Meningitis b vaccine tested as gonorrhea shield in men
NCT ID NCT05766904
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether a meningitis B vaccine (Bexsero) can prevent gonorrhea infections in men who have sex with men. 150 participants in Hong Kong will receive either the vaccine or a placebo. Researchers will compare infection rates and monitor safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 4CMenB vaccine (Bexsero)
- What this could lead to
- If it works, this could point toward a new way to prevent gonorrhea, a common sexually transmitted infection, using an existing vaccine.
- What could go wrong
- This is a small, early-stage trial with only 150 men in Hong Kong. The vaccine may not prove effective, and results may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GONORRHEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanley Ho Centre for Emerging Infectious Diseases
Shatin, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple antibiotic dosing schedule be key to STI prevention?
- Pocket-sized HIV test could bring same-day diagnosis to community clinics
- Could routine STI screening during pregnancy prevent preterm births?
- New trial combines HIV PrEP and STI prevention in one package for young men
- New study uses DNA to track hidden gonorrhea in partners
- Can a common antibiotic prevent STIs? new study tests two dosing strategies